benign prostatic hyperplasia


Also found in: Thesaurus, Medical, Acronyms, Encyclopedia, Wikipedia.

benign prostatic hyperplasia

n.
A nonmalignant enlargement of the prostate gland commonly occurring in men after the age of 50, and sometimes leading to compression of the urethra and obstruction of the flow of urine.
ThesaurusAntonymsRelated WordsSynonymsLegend:
Noun1.benign prostatic hyperplasia - enlarged prostate; appears to be part of the natural aging process
hyperplasia - abnormal increase in number of cells
References in periodicals archive ?
Within the past decade, a number of significant advancements have occurred in our knowledge of benign prostatic hyperplasia (BPH) resulting in new approaches to both the diagnosis and treatment of this common and potentially progressive condition of aging men.
The ThermaStent is the second stent device developed for Endocare's benign prostatic hyperplasia product line.
Fore Pharma's latest report 'Global Benign Prostatic Hyperplasia Drug Pipeline Capsule - 2012 Update' provides most up-to-date information on key Research and Development activities (R&D) in the global Benign Prostatic Hyperplasia market.
Nymox Pharmaceutical, a company that researches and develops neurological diagnostics and pharmaceuticals for the aging population with emphasis on Alzheimer's disease, has completed the enrolment of patients in pivotal US Phase 3 benign prostatic hyperplasia study of NX-1207, it was reported yesterday.
Review of key trends in the development of new benign prostatic hyperplasia drugs across the seven major markets.
Biopharmaceutical company Nymox Pharmaceutical Corporation (NasdaqCM:NYMX) said on Monday that it has initiated its NX02-0022 clinical trial of NX-1207 for benign prostatic hyperplasia (BPH) on 70 US clinical trial sites.
In 2011, Cialis 5mg for once daily use was approved by the US Food and Drug Administration for the treatment of the signs and symptoms of BPH and for the treatment of men who have both erectile dysfunction and the signs and symptoms of benign prostatic hyperplasia (ED+BPH).
The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Benign Prostatic Hyperplasia.
4 million prevalent cases of benign prostatic hyperplasia (BPH) in men over age 50 in the seven major markets (the US, Japan, France, Germany, Italy, Spain, and the UK); approximately 49% of these cases were symptomatic.
Coverage of the Benign Prostatic Hyperplasia pipeline on the basis of therapeutic class, route of administration and molecule type.
The Benign Prostatic Hyperplasia Therapeutics Market is Forecast to Show Modest Growth Until 2016

Full browser ?